Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
3.210
-0.170 (-5.03%)
Mar 31, 2025, 10:55 AM EDT - Market open
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 28 employees as of December 31, 2023. The number of employees decreased by 1 or -3.45% compared to the previous year.
Employees
28
Change (1Y)
-1
Growth (1Y)
-3.45%
Revenue / Employee
n/a
Profits / Employee
-$2,224,750
Market Cap
218.72M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
CRVS News
- 3 days ago - Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials - Seeking Alpha
- 3 days ago - Corvus Pharmaceuticals: Now At Cruising Altitude - Seeking Alpha
- 5 days ago - Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 11 days ago - Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma - GlobeNewsWire
- 11 days ago - Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - GlobeNewsWire
- 13 days ago - Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 - GlobeNewsWire
- 19 days ago - Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) - GlobeNewsWire